{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024402","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.952753+00:00","generated_at":"2026-05-16T18:12:06.206374+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MAIA starts Romania enrollment for Phase 2 THIO-101 Part C; 38% ORR vs standard 6% cited","bullets":["CEO presented at Smart Diaspora 2025; Romania begins screening patients for THIO-101 Part C.","Observed 38% overall response rate vs current third-line NSCLC treatments with ~6% response rate.","FDA Fast Track Designation for ateganosine received in July 2025, supports accelerated approval path.","Third-line NSCLC patients resistant to chemo and immunotherapy are target population.","Investigator Tudor Ciuleanu, MD, PhD, is key opinion leader in Eastern Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024402","json":"https://secwatch.observer/filing/0001493152-25-024402.json","markdown":"https://secwatch.observer/filing/0001493152-25-024402.md","text":"https://secwatch.observer/filing/0001493152-25-024402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225024402/0001493152-25-024402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225024402/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:12:06.206374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}